

People

Appointments

Gerard Le Fur appointed Senior Executive VP of Sanofi-Synthelabo

The Sanofi-Synthelabo Board of Directors (<http://www.sanofi-synthelabo.com>) has announced the appointment of Gerard Le Fur as Senior Executive Vice President. Le Fur will retain his responsibilities as Executive VP in charge of scientific affairs.

Le Fur joined Sanofi in 1986 as Associate Director of R&D and was appointed Director of R&D in 1995 and Executive VP in 1998.

Born in 1950, Le Fur – a doctor in pharmacy and science – has had a role in several fields in the development of medicines and is a specialist in the area of CNS disorders.

Spinx Laboratories names new Director

Eli Lilly's Sphinx Laboratories (<http://www.sphinxlabs.com>) have announced the appointment of Robert Pacifici, as Chief Scientific Officer and Site Director. Pacifici will provide strategic organizational leadership for the scientific and technical direction for Sphinx.

Robert Armstrong, Vice President for discovery chemistry research technology at Lilly, said: 'We are thrilled to have someone of Robert's calibre and experience join the Sphinx organization. Robert's key contributions in the areas of HTS, technology and informatics will have a productive impact on the continued evolution of our lead generation biology.'

Pacifici joins Lilly from Xencor, where he was VP for discovery technologies. Prior to this, he held scientific and leadership positions at Amgen.

New President and CEO at Locus Discovery

H. Joseph Reiser has been appointed President and CEO and will join the Board of Directors at Locus Discovery (<http://www.locusdiscovery.com>), a company focused on developing novel, small molecule therapeutics.

Reiser was most recently President and CEO of Cytogen and will continue to serve on their Board of Directors. He has over 22 years of experience in the pharmaceutical

and biotechnology industries. Prior to his five years at Cytogen, he gained substantial experience at Berlex Laboratories.

Duane Mason, Chairman of the Board of Directors at Locus, said: 'Reiser is ideally suited to lead Locus in its mission to rapidly develop novel, small molecule-based therapeutics utilizing proprietary computational technologies.'

Reiser has a proven track record of raising capital, forging alliances and designing and executing strategic plans in both large and small company environments.'

On his appointment, Reiser stated, 'This is an exceptional opportunity... Given the plethora of genomic and proteomic targets available today, the need to evolve such targets more efficiently is paramount to fulfilling a critical need for the pharmaceutical industry.'

Key additions to Renovis Management Team

Renovis (<http://www.renovis.com>), a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for neurological diseases, has announced some key additions to its Management Team.

The appointments are: John C. Doyle as Vice President of Finance and Chief Financial Officer; F. Jacob Huff as VP of Clinical Development; Michael G. Kelly as Senior Director of Chemistry; John A. Kollins as VP of Business development; and Paul Serbin as VP of Human Resources.

Corey Goodman, President and CEO of Renovis, said: 'We now have in place an experienced team [that is] capable of managing a discovery and development company with active discovery research, preclinical and clinical development programs, including several late stage products.'

Doyle brings over a decade of experience in finance, previously at Garage Technology Ventures and Tularik; Huff has over 15 years of experience in the clinical development of drugs to treat neurological and psychiatric disease; Kelly brings over 20 years of experience in drug discovery from Amgen, Wyeth and Wellcome (now GSK); Kollins has over a decade of commercial and strategic partnering experience, at SurroMed, Athena Neurosciences, Elan and Immunex; and Serbin has over 20 years

experience in human resources in early-stage as well as Fortune-500 companies, including Exelixis and Genzia.

Ronald D. Moss departs The Immune Response Corporation

The Immune Response Corporation (IMNR; <http://www.imnr.com>), has announced the departure of Ronald B. Moss, who had been President of the company since September 2002. Moss is leaving for a position with Merck.

Jon N. Bonfiglio, CEO of IMNR, said: 'We are saddened to see Ron leave the company. His insights and hard work on combating the HIV/AIDS epidemic throughout his entire career have been an inspiration to many people here.'

Moss joined IMNR as Medical Director in 1994, and was named VP, Medical and Scientific Affairs in January 2000.

The Immune Response Corporation develops immune-based therapies designed to treat HIV, autoimmune diseases and cancer.

Neurochem appoints Philippe Calais as President

Francesco Bellini, Chairman and CEO of Neurochem (<http://www.neurochem.com>), has announced the appointment of Philippe Calais as President of the company. Calais brings two decades of expertise in the pharmaceutical industry, including international business development and strategic marketing, extending from senior administration, regulatory affairs, R&D, staff training to incentive programs.

Before joining Neurochem, Calais was General Manager of Servier Canada, where he successfully launched two new products to strengthen the profitability of the sales force while expanding market coverage.

Bellini said, 'With Neurochem now approaching the market with one of its key product candidates... Calais's international background in key areas of pharmaceutical industry management will be important to guide the introduction of the company's future products in the global market place.'

Neurochem is a product-driven, speciality pharmaceutical company offering a new class of drug candidates to prevent and halt the progression of disease for which there is no cure.

People was written by
Joanne Clough